BriaCell Therapeutics Corp.

Nasdaq: BCTX, BCTXW, BCTXZ
TSX: BCT

Share Price (Dec 11)	US$8.98
Basic Shares Out	1.9M
Basic Market Cap	US$17.1M

William V. Williams, MD, FACP
President & CEO, Director

- Former VP, Exploratory Development, Incyte
- Former VP, Experimental Medicine, GlaxoSmithKline
- 11 drug approvals

Jamieson Bondarenko, CFA, CMT
Chairman of the Board

- Former Managing Director, Equity Capital Markets, Eight Capital
- Former Managing Director, Dundee Securities Ltd.

WHO ARE WE?

- A clinical stage immunotherapy company driven to fight cancer and improve patients' lives
- Lead asset Bria-IMT™ boosts the ability of the body's own cancer-fighting cells to destroy cancer
- **Ongoing pivotal Phase 3 registration study** in breast cancer under FDA Fast Track Designation
  - Advanced metastatic breast cancer causes over **40,000 deaths per year** in the U.S.
- Up to 2-fold increase in survival vs. comparable patients in the literature
- Remarkable clinical efficacy data in patients with CNS (brain) metastases



WHAT WE DO:

1. **Express tumor antigens and GM-CSF to activate specific cancer fighting CD4+ and CD8+ T cells**
2. **Directly stimulate the immune system to enhance targeted killing of cancer cells**

HOW ARE PATIENTS RESPONDING?

Safety & efficacy data similar or superior to that of approved breast cancer drugs when used to treat similar (advanced stage) patients

- **Phase 2 Bria-IMT metastatic breast cancer study**
- Overall survival (OS) of **13.4 months** in patients treated with phase 3 formulation (n=37) vs. 5.9-9.8 months* in similar metastatic breast cancer patients who have failed 2+ prior therapy attempts
- OS of **17.3 months** in patients treated with phase 3 formulation since 2022 (n=25)
- Similar responses seen in patients resistant to Antibody Drug Conjugates (ADCs) and Check Point Inhibitors (CPIs)
- Acceptable safety profile to date

REMARKABLE RESPONDERS HIGHLIGHTED



- Patient failed 13 prior treatment regimens
- Tumor causing left eye proptosis (eye bulging) completely resolved



- Patient failed 8 prior regimens including ADC Enhertu®
- 100% resolution of brain metastasis and improvement elsewhere

* Cortes J, et al. Annals of Oncology 2018; Kazmi S, et al. Breast Cancer Res Treat. 2020 Aug 17; O'Shaughnessy J et al. Breast Cancer Res Treat. 2022; Tripathy D, et al. JAMA Oncol. 2022; Bardia A, et al. J Clin Oncol. 2024 May 20;42(15):1738-1744

BriaCell Therapeutics Corp.

Nasdaq: BCTX, BCTXW
TSX: BCT

WHAT DOES FDA THINK?

FDA U.S. FOOD & DRUG ADMINISTRATION

- Fast-Track designation granted
- Phase 2a directly into pivotal Phase 3 study
- Survival-related end points for pivotal study
- Single Phase 3 study for approval (no confirmatory study required)

HOW DO WE GET FDA APPROVAL?

- **Analyze at 144 events (deaths)**
  - If hazard ratio (HR) is ≤ 0.6… approved!
  - If > 0.6, continue to completion with HR target of 0.7



WHAT'S NEXT?

- **Bria-OTS™ (*off-the-shelf approach*)** Phase 1/2a clinical trial enrolling
  - **BriaCell** immunotherapy is most effective in human leukocyte antigen (HLA) type matched patients
  - **Bria-OTS** expresses 15 unique HLA types, providing off the shelf matched treatment to >99% of patients
  - Simple saliva test delivers personalized Bria-OTS immunotherapy
  - **Platform technology for breast, prostate, lung, melanom**



Results of first patient treated:

- **Complete resolution of lung lesion at two months**
- **Stable disease elsewhere**